Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Ann Intern Med

Retrieve available abstracts of 7 articles:
HTML format



Single Articles


    September 2023
  1. ROWAN C
    In moderate-to-severe Crohn disease, upadacitinib increased clinical remission at 12 and 52 wk.
    Ann Intern Med. 2023 Sep 5. doi: 10.7326/J23-0069.
    PubMed     Abstract available


    July 2023
  2. AL-JABRI R, Afif W
    In moderately to severely active UC, etrasimod increased remission at 12 and 52 wk but increased adverse events.
    Ann Intern Med. 2023;176:JC82.
    PubMed     Abstract available


    October 2022
  3. OLIVER D, Talley NJ
    In active Crohn disease, risankizumab increased clinical remission and endoscopic response at 12 wk.
    Ann Intern Med. 2022 Oct 4. doi: 10.7326/J22-0080.
    PubMed     Abstract available


  4. FORBES GM
    In active UC, upadacitinib induced and maintained remission.
    Ann Intern Med. 2022;175:JC113.
    PubMed     Abstract available


    September 2022
  5. MEYER A, Neumann A, Drouin J, Weill A, et al
    Benefits and Risks Associated With Continuation of Anti-Tumor Necrosis Factor After 24 Weeks of Pregnancy in Women With Inflammatory Bowel Disease : A Nationwide Emulation Trial.
    Ann Intern Med. 2022 Sep 27. doi: 10.7326/M22-0819.
    PubMed     Abstract available


    December 2021

  6. Correction: Antibody Responses After SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease.
    Ann Intern Med. 2021;174:1780.
    PubMed    


    October 2021
  7. MELMED GY, Botwin GJ, Sobhani K, Li D, et al
    Antibody Responses After SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease.
    Ann Intern Med. 2021 Oct 12. doi: 10.7326/M21-2483.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.